Frequencies are reported as: Very common: (≥1/10); Common: (≥1/100 to <1/10); Uncommon: (≥1/1,000 to <1/100); Rare: (≥1/10,000 to <1/1,000); Very rare: (<1/10,000). (See Table 5.)
Click on icon to see table/diagram/image
In a comparative trial in subjects from 11 years up to and including 15 years of age, the incidence of local and general solicited symptoms reported after a two-dose regimen of Engerix-B 20 μg was similar overall to that reported after the standard three-dose regimen of Engerix-B 10 μg.
View ADR Monitoring Form